Clinical Research Associate - Multi-Sponsored Model
About the job
- A Bachelor's degree in a health care or other scientific discipline or educational equivalent.
- At least 1.5–2 years of on-site monitoring experience.
- Fluency in Arabic and English.
- Good written and verbal communication skills, including good command of English.
- Good basic knowledge of applicable clinical research regulatory requirements.
- Willingness to travel frequently to sites.
- Flexibility about location, provided the location has good connectivity to travel.
- Ability to work home-based.
- Perform site selection, initiation, monitoring, and close-out visits, while maintaining appropriate documentation.
- Support the development of a subject recruitment plan.
- Establish regular lines of communication and administer protocol and related study training to assigned sites.
- Evaluate the quality and integrity of site practices and escalate quality issues as appropriate.
- Manage progress by tracking regulatory submissions, recruitment, case report form completion, and data query resolution.
About the company
IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Get referred to IQVIA
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 revenue rose 8.7%; R&DS bookings jumped 19% to $3.15 billion.
- Predictive Clinical Development claims 33% faster startup and 50% faster data cleaning.
- September 23, 2026 $2 billion notes refinance 2026 maturities and extend the debt runway.
What critics are saying
- Italy fined IQVIA €7 million on September 23, 2026 over reidentifiable patient data.
- June 30, 2026 net debt reached $13.9 billion, pressuring flexibility after the 6.375% notes.
- A Europe-wide privacy ruling can force IQVIA to rebuild data pipelines and shrink margins.
What makes IQVIA unique
- IQVIA serves 19 of top 20 pharma companies with regulated healthcare data and trials.
- September 3, 2026 Predictive Clinical Development compresses trial timelines using proprietary data and AI.
- IQVIA.ai and NVIDIA partnerships deepen its closed-loop commercial and development workflow.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↑ 0%The Italian Italy's Data Protection Authority fines IQVIA €7 million over data protection breach. The following is a machine translation of a press release by Italy's privacy guarantor: Healthcare data: The Privacy Guarantor fines IQVIA 7 million euros. The data of one million patients of 800 family doctors are not anonymous. The Italian Data Protection Authority has fined IQVIA Solutions Italy Srl €7 million. The company, part of a... Introduction to Malware Binary Triage (IMBT) Course Looking to level up your skills? Get 10% off using coupon code: MWNEWS10 for any flavor. Enroll Now and Save 10%: Coupon Code MWNEWS10 Note: Affiliate link - your enrollment helps support this platform at no extra cost to you. New & unread topics.
IQVIA MedTech introduces Surgical Collaboration Platform to help scale surgeon education. IQVIA MedTech is highlighting its Surgical Collaboration Platform (SCP), a purpose-built platform designed to help MedTech organizations coordinate and track peer-to-peer surgeon education across the engagement lifecycle. As medical device companies introduce increasingly sophisticated devices, robotic systems, implants and surgical tools, clinician education can play a critical role in supporting technology adoption. However, the infrastructure behind these programs can remain fragmented, with education teams coordinating faculty availability, learner requests, scheduling, credentialing and documentation across spreadsheets, email and disconnected systems. The IQVIA MedTech Surgical Collaboration Platform is designed to bring those activities into a more connected workflow. The platform helps clinicians and education teams manage surgeon requests, credentialing, host-surgeon identification, faculty and site availability, scheduling, documentation, training completion and program reporting. The platform is intended to address an infrastructure challenge that can become increasingly complex as new technologies reach additional surgeons, sites and markets. By creating greater visibility across the education journey, IQVIA aims to help MedTech organizations more effectively coordinate and scale surgeon-to-surgeon education.
IQVIA stock has risen 60.1% over the past six months, outpacing the industry's 4.1% return and the S&P 500's 14% rally. The company's strong performance is driven by accelerating organic growth, with second-quarter 2026 revenue rising 6% year over year. Research & Development Solutions grew 7% organically, whilst the commercial side increased 5%. IQVIA's R&DS net new bookings jumped 19.3% year over year in Q2 2026, producing a book-to-bill ratio of 1.22. Backlog reached $34.2 billion at the end of June. The company has deployed 294 AI agents across 90 use cases. Nineteen of the top 20 pharmaceutical companies have adopted IQVIA's solutions, strengthening its competitive position.
IQVIA Holdings announced its subsidiary IQVIA Inc. priced an offering of $2 billion in senior notes due 2034. The notes will bear interest at 6.375% per annum, with semi-annual payments beginning 15 March 2027, and mature on 15 March 2034. Proceeds will be used to redeem the company's senior 5.000% notes due 2026, repay part of its outstanding revolving credit facility debt, and cover offering fees and expenses. The issuance is expected to close on or about 23 September 2026, subject to customary conditions. IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries, employing approximately 94,000 people across over 100 countries.
HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18). September 4, 2026 Hyman, Phelps & McNamara, P.C.'s Karla Palmer and Andrew Hull will be speaking again at IQVIA's 28th Annual Controlled Substance & State Regulatory Conference in Scottsdale, AZ (Sept. 16-18). As part of a stacked agenda that runs the gamut on controlled substances issues, Ms. Palmer will speak on compliance considerations for compounders, and Mr. Hull will present on how registrants can mitigate risk and preserve reputation during a DEA investigation. Mr. Hull will also be presenting a course with retired DEA Chief Administrative Law Judge John J. Mulrooney, II, a partner at Belanger Rae & Mulrooney, on protecting your rights in DEA administrative actions. Join FDA Law Blog in Scottsdale for what promises to be another educational conference with key thought leaders and industry experts. Register here. Search FDA Law Blog. Subscribe. Never miss a post from FDA Law Blog